University Hospital HD / Sumaya Biotech: New vaccine candidate against malaria successfully tested in first clinical trial
A novel vaccine candidate against the causative agent of malaria tropica, the most severe form of human malaria, has now been successfully tested for safety, tolerability and immunogenicity (ability to produce antibodies). Experts of the Department of Clinical Pharmacology and Pharmacoepidemiology of the University Hospital Heidelberg (directed by Prof. Dr. med. Walter E. Haefeli) led the phase Ia clinical trials commissioned by Sumaya Biotech GmbH & Co. KG . The vaccine candidate SumayaVac1 was selected in the working group of Prof. Dr. med. Hermann Bujard at the Center for Molecular Biology of the University of Heidelberg (ZMBH).
Read entire press release (in German).